Source: Pharmaceutical Business Review

F-star: invoX Pharma completes acquisition of F-star Therapeutics for $161m

F-star is being acquired for a total cash consideration of approximately $161m or $7.12 per share. Currently, F-star is undertaking Phase II trials in Europe and the US. The post invoX Pharma completes acquisition of F-star Therapeutics for $161m appeared first on Pharmaceutical Business review.

Read full article »
F-star's Competitors | F-star's News | F-star's Financials
Stay up-to-date with the latest news on F-star
Annual Revenue
$5.0-25M
Employees
25-100
Eliot Forster's photo - CEO of F-star

CEO

Eliot Forster

CEO Approval Rating

88/100

Read more
Stay up-to-date with the latest news on F-star